We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




RT-PCR Assay Detects and Differentiates Parainfluenza Viruses

By LabMedica International staff writers
Posted on 21 Apr 2009
A real time-polymerase chain reaction (RT-PCR) assay rapidly detection and differentiates parainfluenza viruses 1, 2, and 3.

Real-time technology offers clear advantages over other molecular diagnostic techniques such as microbeads and microarrays because little hands-on time is required, risk of amplicon contamination is eliminated, equipment cost is relatively low, and inducement concerns (resulting from running a large panel of tests, some of which may not be medically-indicated) are minimized.

The ProParaflu+ assay is an in vitro diagnostic product; it yields an objective answer within 3 hours. More...
It is a product of Prodesse Inc. (Milwaukee, WI, USA), a biotechnology company focused on developing molecular diagnostic reagents for a variety of infectious disease applications. Together with ProFlu+ (for influenza viruses) and Pro hMPV+ (for metapneumovirus) the three respiratory products offer seven detections and share an internal control. This enables clinicians to easily run the most appropriate series of tests for their patients from just a single nucleic acid extraction.

Human parainfluenza viruses are a common cause of respiratory infections, especially in children; it is second only to respiratory syncytial virus as a cause of hospitalization of pediatric patients. Parainfluenza 1 virus is the leading cause of croup in children. Parainfluenza 3 is often associated with bronchiolitis and pneumonia. The elderly and the immunocompromised are also at higher risk for lower respiratory tract infections from parainfluenza viruses. Current methods for detection require subjective interpretation from highly skilled laboratory technicians and can take several days to provide a result.

The Prodesse's products can be used on multiple nucleic acid extraction and RT-PCR platforms. The company has filed a submission with the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) for 510(k) clearance to market its ProParaflu+ assay in the United States.

Related Links:

Prodesse Inc.
U.S. Food and Drug Administration




Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.